US2013196427A1PendingUtilityA1
Cancer antigen peptides derived from wt1
Assignee: INT INST CANCER IMMUNOLOGY INCPriority: Mar 31, 2004Filed: Jan 24, 2013Published: Aug 1, 2013
Est. expiryMar 31, 2024(expired)· nominal 20-yr term from priority
Inventors:Haruo Sugiyama
A61P 35/00G01N 33/56972C07K 16/30A61K 38/00A61K 48/00C07K 14/4748A61K 40/4243A61K 40/11C12N 5/0638A61K 39/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A CTL, which recognizes a complex between an HLA-A26-binding cancer antigen peptide derived from the amino acid sequence of human WT1 set forth in SEQ ID NO: 1 and HLA-A26 antigen.
20 . The CTL according to claim 19 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 9.
21 . The CTL according to claim 20 , wherein the length of the peptide is up to 11 amino acids.
22 . The CTL according to claim 19 , wherein the peptide comprises an amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 9 except that one to several amino acids are substituted, deleted and/or added.
23 . The CTL according to claim 19 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 2.
24 . The CTL according to claim 19 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 8.
25 . The CTL according to claim 19 , wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 9.Join the waitlist — get patent alerts
Track US2013196427A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.